YM155 exerts potent cytotoxic activity against quiescent (G0/G1) multiple myeloma and bortezomib resistant cells <i>via</i> inhibition of survivin and Mcl-1

• Miyuki Ookura

  Department of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan

• Tatsuya Fujii

  Department of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan

• Hideki Yagi

  Department of Pharmaceutical Sciences, International University of Health and Welfare, Otawara, Tochigi 324-8501, Japan

• Takuya Ogawa

  Department of Pharmaceutical Sciences, International University of Health and Welfare, Otawara, Tochigi 324-8501, Japan

• Shinji Kishi

  Department of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan

• Naoko Hosono

  Department of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan

• Hiroko Shigemi

  Department of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan

• Takahiro Yamauchi

  Department of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan

• Takanori Ueda

  Department of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan

• Akira Yoshida

  Department of Hematology, International University of Health and Welfare Hospital, Iguchi, Nasushiobara, Tochigi, 329-2763, Japan

Journal

• Oncotarget

  Oncotarget 8 (67), 111535-111550, 2017-12-04

  Impact Journals, LLC

Keywords

• Oncology

Details

• CRID: 1360285713249267200
• NII Article ID: 120006469617
• DOI: 10.18632/oncotarget.22871
• ISSN: 19492553
• Web Site: https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.22871
• Data Source:
  • Crossref
  • CiNii Articles
  • KAKEN